Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D; European Neuroblastoma Study Group; Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group).

Lancet Oncol. 2008 Mar;9(3):247-56. doi: 10.1016/S1470-2045(08)70069-X.

PMID:
18308250
2.

Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.

Peinemann F, Tushabe DA, van Dalen EC, Berthold F.

Cochrane Database Syst Rev. 2015 May 19;(5):CD010774. doi: 10.1002/14651858.CD010774.pub2. Review.

PMID:
25989478
3.

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR.

Pediatr Blood Cancer. 2005 Apr;44(4):348-57.

PMID:
15546135
4.

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.

Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, Kogner P, Garami M, Balwierz W, Schroeder H, Beck-Popovic M, Schreier G, Machin D, Pötschger U, Pearson A.

J Clin Oncol. 2010 Jul 20;28(21):3516-24. doi: 10.1200/JCO.2009.27.3524. Epub 2010 Jun 21.

5.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
6.

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B.

Lancet Oncol. 2005 Sep;6(9):649-58.

PMID:
16129365
7.

OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.

Tweddle DA, Pinkerton CR, Lewis IJ, Ellershaw C, Cole M, Pearson AD.

Med Pediatr Oncol. 2001 Jan;36(1):239-42.

PMID:
11464894
8.

Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification.

Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T, Suita S.

J Pediatr Hematol Oncol. 2002 Nov;24(8):613-21.

PMID:
12439032
9.

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S.

Lancet Oncol. 2013 Mar;14(3):199-209. doi: 10.1016/S1470-2045(12)70600-9. Epub 2013 Feb 7.

11.

Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.

Tobias JS, Monson K, Gupta N, Macdougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A; UK Head and Neck Cancer Trialists' Group.

Lancet Oncol. 2010 Jan;11(1):66-74. doi: 10.1016/S1470-2045(09)70306-7. Epub 2009 Oct 29.

12.

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J, Sommelet D.

J Clin Oncol. 1997 Mar;15(3):1171-82.

PMID:
9060561
13.

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.

Delarue R, Tilly H, Mounier N, Petrella T, Salles G, Thieblemont C, Bologna S, Ghesquières H, Hacini M, Fruchart C, Ysebaert L, Fermé C, Casasnovas O, Van Hoof A, Thyss A, Delmer A, Fitoussi O, Molina TJ, Haioun C, Bosly A.

Lancet Oncol. 2013 May;14(6):525-33. doi: 10.1016/S1470-2045(13)70122-0. Epub 2013 Apr 9.

PMID:
23578722
14.

Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.

Bomken S, Davies B, Chong L, Cole M, Wood KM, McDermott M, Tweddle DA.

Pediatr Hematol Oncol. 2011 Mar;28(2):106-14. doi: 10.3109/08880018.2010.526684. Epub 2011 Jan 8.

PMID:
21214410
15.

Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.

Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB.

J Pediatr Hematol Oncol. 2001 May;23(4):225-33.

PMID:
11846301
16.

Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.

Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, Rubie H, Coze C, Plantaz D, Bernard F, Chastagner P, Bouzy J, Hartmann O.

J Clin Oncol. 2005 Jan 20;23(3):532-40.

17.

Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.

Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA.

J Clin Oncol. 1994 Aug;12(8):1616-20.

PMID:
8040674
18.

Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.

Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, Schuck A, Winkelmann W, Köhler G, Poremba C, Zoubek A, Ladenstein R, van den Berg H, Hunold A, Cassoni A, Spooner D, Grimer R, Whelan J, McTiernan A, Jürgens H; European Intergroup Cooperative Ewing's Sarcoma Study-92.

J Clin Oncol. 2008 Sep 20;26(27):4385-93. doi: 10.1200/JCO.2008.16.5720.

19.

Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.

Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup.

J Natl Cancer Inst. 2007 Jan 17;99(2):112-28.

20.

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.

Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E 3rd, Ayash L.

Bone Marrow Transplant. 2001 Feb;27(3):269-78.

Items per page

Supplemental Content

Write to the Help Desk